- Home
- ONEG vs CTXR Comparison
ONEG vs CTXR Comparison
Compare ONEG & CTXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ONEG | CTXR |
|---|---|---|
| Founded | 2021 | 2007 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 18.7M |
| IPO Year | 2024 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ONEG | CTXR |
|---|---|---|
| Price | $1.04 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 39.2K | ★ 890.2K |
| Earning Date | 01-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 43.38 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $147.57 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.72 | $0.47 |
| 52 Week High | $14.95 | $2.19 |
Technical Indicators
Market Signals| Indicator | ONEG | CTXR |
|---|---|---|
| Relative Strength Index (RSI) | 44.61 | 48.46 |
| Support Level | $1.01 | $0.51 |
| Resistance Level | $1.10 | $0.61 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 41.75 | 19.72 |
Price Performance
Historical ComparisonAbout ONEG OneConstruction Group Limited Ordinary Shares
OneConstruction Group Ltd is a structural steelwork contractor in Hong Kong. The company is engaged in the procurement and installation of structural steel for construction projects in Hong Kong. Its construction project includes performing site preparatory and preliminary works, developing detailed work schedules and work allocation plans, implementing construction site works, and conducting site safety supervision and quality control.
About CTXR Citius Pharmaceuticals Inc.
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.